Fulgent Genetics, Inc. (FLGT)
USD 18.74
(-3.6%)
USD 18.74
(-3.6%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 104.45 Million USD | -73.67% |
| 2022 | 366.9 Million USD | -52.78% |
| 2021 | 777.05 Million USD | 134.12% |
| 2020 | 331.9 Million USD | 1701.78% |
| 2019 | 18.42 Million USD | 72.72% |
| 2018 | 10.66 Million USD | 4.77% |
| 2017 | 10.17 Million USD | -11.91% |
| 2016 | 11.55 Million USD | 156.38% |
| 2015 | 4.5 Million USD | 1217.84% |
| 2014 | 342 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 20.11 Million USD | -13.57% |
| 2024 Q2 | 24.5 Million USD | 21.81% |
| 2023 Q1 | 18.81 Million USD | 44.84% |
| 2023 FY | 96.61 Million USD | -73.67% |
| 2023 Q4 | 23.27 Million USD | -41.59% |
| 2023 Q3 | 39.84 Million USD | 93.68% |
| 2023 Q2 | 20.57 Million USD | 9.36% |
| 2022 Q3 | 46.09 Million USD | -29.38% |
| 2022 FY | 366.9 Million USD | -52.78% |
| 2022 Q1 | 242.54 Million USD | 27.97% |
| 2022 Q2 | 65.27 Million USD | -73.09% |
| 2022 Q4 | 12.98 Million USD | -71.83% |
| 2021 Q4 | 189.53 Million USD | 2.78% |
| 2021 FY | 777.05 Million USD | 134.12% |
| 2021 Q1 | 285.35 Million USD | 17.33% |
| 2021 Q3 | 184.4 Million USD | 56.59% |
| 2021 Q2 | 117.75 Million USD | -58.73% |
| 2020 Q4 | 243.2 Million USD | 222.32% |
| 2020 Q1 | 3.69 Million USD | -22.24% |
| 2020 Q2 | 9.54 Million USD | 158.33% |
| 2020 Q3 | 75.45 Million USD | 690.27% |
| 2020 FY | 331.9 Million USD | 1701.78% |
| 2019 Q2 | 4.8 Million USD | 100.0% |
| 2019 Q3 | 6.46 Million USD | 34.51% |
| 2019 Q4 | 4.75 Million USD | -26.45% |
| 2019 FY | 18.42 Million USD | 72.72% |
| 2019 Q1 | 2.4 Million USD | -17.6% |
| 2018 Q3 | 3.01 Million USD | 5.5% |
| 2018 Q1 | 1.88 Million USD | 8.35% |
| 2018 FY | 10.66 Million USD | 4.77% |
| 2018 Q4 | 2.91 Million USD | -3.25% |
| 2018 Q2 | 2.85 Million USD | 51.83% |
| 2017 Q1 | 3.44 Million USD | -13.63% |
| 2017 FY | 10.17 Million USD | -11.91% |
| 2017 Q4 | 1.73 Million USD | -22.33% |
| 2017 Q3 | 2.23 Million USD | -19.05% |
| 2017 Q2 | 2.76 Million USD | -19.9% |
| 2016 Q3 | 2.91 Million USD | 13.75% |
| 2016 Q1 | 2.13 Million USD | 1120.57% |
| 2016 Q2 | 2.56 Million USD | 19.85% |
| 2016 Q4 | 3.99 Million USD | 37.05% |
| 2016 FY | 11.55 Million USD | 156.38% |
| 2015 Q1 | 935 Thousand USD | 0.0% |
| 2015 Q2 | 1.4 Million USD | 50.7% |
| 2015 Q4 | 175 Thousand USD | -91.19% |
| 2015 Q3 | 1.98 Million USD | 41.02% |
| 2015 FY | 4.5 Million USD | 1217.84% |
| 2014 FY | 342 Thousand USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | -991.951% |
| Prenetics Global Limited | 8.82 Million USD | -1082.982% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -775.868% |
| CareDx, Inc | 178.32 Million USD | 41.424% |
| Exact Sciences Corporation | 1.84 Billion USD | 94.34% |
| Exagen Inc. | 29.45 Million USD | -254.617% |
| Inotiv, Inc. | 165.44 Million USD | 36.863% |
| Guardant Health, Inc. | 336.89 Million USD | 68.995% |
| Biodesix, Inc. | 36.07 Million USD | -189.536% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | -7756.8% |
| Precipio, Inc. | 6.01 Million USD | -1635.726% |
| iSpecimen Inc. | 5.1 Million USD | -1944.983% |
| Natera, Inc. | 492.74 Million USD | 78.801% |
| Aspira Women's Health Inc. | 5.26 Million USD | -1885.101% |
| Standard BioTools Inc. | 50.45 Million USD | -107.049% |
| 23andMe Holding Co. | 99.37 Million USD | -5.111% |
| Castle Biosciences, Inc. | 174.8 Million USD | 40.245% |
| Personalis, Inc. | 18.2 Million USD | -473.682% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | -693.256% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | -1787.725% |
| OpGen, Inc. | -90.69 Thousand USD | 115274.102% |
| T2 Biosystems, Inc. | -8.17 Million USD | 1378.531% |
| Myriad Genetics, Inc. | 476.4 Million USD | 78.074% |
| ICON Public Limited Company | 1.81 Billion USD | 94.243% |
| NeoGenomics, Inc. | 244.6 Million USD | 57.296% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -775.868% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 95.23% |
| RadNet, Inc. | 93 Million USD | -12.318% |
| MDxHealth SA | 43.92 Million USD | -137.784% |
| Psychemedics Corporation | 8.41 Million USD | -1141.602% |
| Illumina, Inc. | 2.74 Billion USD | 96.193% |
| Check-Cap Ltd. | -212 Thousand USD | 49371.698% |
| Twist Bioscience Corporation | 133.34 Million USD | 21.667% |
| DarioHealth Corp. | 5.98 Million USD | -1645.588% |
| Sera Prognostics, Inc. | 96 Thousand USD | -108708.333% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 38021.808% |
| OPKO Health, Inc. | 318.12 Million USD | 67.165% |
| Medpace Holdings, Inc. | 524.5 Million USD | 80.085% |
| Neogen Corporation | 463.9 Million USD | 77.483% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | -7227.027% |
| Prenetics Global Limited | 8.82 Million USD | -1082.982% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -20395.272% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -13095.303% |
| Trinity Biotech plc | 19.45 Million USD | -437.049% |
| Neuronetics, Inc. | 51.7 Million USD | -102.023% |
| Sotera Health Company | 577.15 Million USD | 81.902% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -13095.303% |